Associated Genetic Biomarkers
XRCC4 is altered in 0.54% of all cancers with lung adenocarcinoma and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in XRCC4 are XRCC4 Mutation (0.10%), XRCC4 A249G (0.00%), XRCC4 Loss (0.00%), XRCC4 R161* (0.00%), and XRCC4 R225* (0.00%) .
XRCC4 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains XRCC4 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with XRCC4 status in the inclusion eligibility criteria most commonly target urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is XRCC4 Mutation .
Olaparib is the most frequent therapy in trials with XRCC4 as an inclusion criteria .
Significance of XRCC4 in Diseases
Urothelial Carcinoma +
XRCC4 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.